Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
NCT ID: NCT00099216
Last Updated: 2011-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
708 participants
INTERVENTIONAL
2001-08-31
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rivastigmine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have contact with a responsible caregiver 3 or more days per week
* Be male or a female who is surgically sterilized or one year post menopausal
Exclusion Criteria
* Current diagnosis of active, uncontrolled seizure disorder, Parkinson's disease or Alzheimer's disease
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Irvine, California, United States
San Francisco, California, United States
Boynton Beach, Florida, United States
Miami Beach, Florida, United States
Port Charlotte, Florida, United States
Indianapolis, Indiana, United States
Des Moines, Iowa, United States
St Louis, Missouri, United States
Albuquerque, New Mexico, United States
New York, New York, United States
Portland, Oregon, United States
Allentown, Pennsylvania, United States
Greensburg, Pennsylvania, United States
Charleston, South Carolina, United States
Austin, Texas, United States
Houston, Texas, United States
Bennington, Vermont, United States
Graz, , Austria
Linz, , Austria
Vienna, , Austria
Edmonton, Alberta, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Amiens, , France
Bordeaux, , France
Lille, , France
Marseille, , France
Montpellier, , France
Toulouse, , France
Tours, , France
Bautzen, , Germany
Berlin, , Germany
Bochum, , Germany
Chemnitz, , Germany
Eisenhüttenstadt, , Germany
Erlangen, , Germany
Freiburg im Breisgau, , Germany
Lüdenscheid, , Germany
Osnabrück, , Germany
Ancona, , Italy
Brescia, , Italy
Florence, , Italy
Perugia, , Italy
Reggio Emilia, , Italy
Roma, , Italy
Vicenza, , Italy
Moscow, , Russia
Saint Petersburg, , Russia
Barakaldo, , Spain
Barcelona, , Spain
Madrid, , Spain
Pamplona, , Spain
Saint Cugat Del Valles, , Spain
Basel, , Switzerland
Lausanne, , Switzerland
Newcastle upon Tyne, Newcastle, United Kingdom
Swindon, Wiltshire, United Kingdom
Bristol, , United Kingdom
Clydebank, , United Kingdom
East Sussex, , United Kingdom
Lytham St Annes, , United Kingdom
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin. 2008 Sep;24(9):2561-74. doi: 10.1185/03007990802328142. Epub 2008 Jul 31.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for further information and to find an investigational site near you
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CENA713BIA05
Identifier Type: -
Identifier Source: org_study_id